Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.We performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizu...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Pavord, I, Chanez, P, Criner, G, Kerstjens, H, Korn, S, Lugogo, N, Martinot, J, Sagara, H, Albers, F, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S, Sciurba, F
Formato:	Journal article
Idioma:	English
Publicado em:	Massachusetts Medical Society 2017

Registos relacionados

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Por: Pavord, I, et al.
Publicado em: (2017)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
Por: Bafadhel, M, et al.
Publicado em: (2018)

Mepolizumab for eosinophilic COPD
Por: Sciurba, F, et al.
Publicado em: (2018)

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
Por: Chapman, K, et al.
Publicado em: (2018)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Por: Gunsoy, N, et al.
Publicado em: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Por: Ortega, H, et al.
Publicado em: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Por: Shrimanker, R, et al.
Publicado em: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Por: Mkorombindo T, et al.
Publicado em: (2019-08-01)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Por: Pavord, I, et al.
Publicado em: (2012)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Por: Bel, E, et al.
Publicado em: (2014)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Por: Steven W. Yancey, et al.
Publicado em: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Por: Ortega, H, et al.
Publicado em: (2016)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Por: Yancey, S, et al.
Publicado em: (2016)

Mepolizumab in refractory eosinophilic asthma.
Por: Pavord, I, et al.
Publicado em: (2010)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Por: Pavord, I
Publicado em: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Howell, I, et al.
Publicado em: (2024)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Por: Prazma CM, et al.
Publicado em: (2021-06-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Por: Ian D. Pavord, et al.
Publicado em: (2022-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Por: Imran Howell, et al.
Publicado em: (2024-07-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Por: Terufumi Shimoda, et al.
Publicado em: (2017-07-01)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Por: Wechsler, M, et al.
Publicado em: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Por: Moran, AM, et al.
Publicado em: (2020)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Por: Haldar, P, et al.
Publicado em: (2009)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Por: Ian D. Pavord, et al.
Publicado em: (2020-09-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Por: Mi-Kyeong Kim, et al.
Publicado em: (2021-03-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
Por: Frank C. Albers, et al.
Publicado em: (2019-07-01)

Treatment of eosinophilic myositis with mepolizumab
Por: Saadia Waheed, et al.
Publicado em: (2018-01-01)

GLUCOLD, eosinophils and chronic obstructive pulmonary disease
Por: Pavord, I
Publicado em: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Por: Shrimanker, R, et al.
Publicado em: (2017)

Biomarkers for severe eosinophilic asthma.
Por: Yancey, S, et al.
Publicado em: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Por: Menzella F, et al.
Publicado em: (2016-06-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Por: Shrimanker, R, et al.
Publicado em: (2017)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Por: Moran, A, et al.
Publicado em: (2020)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
Por: Benjamin Terrier, et al.
Publicado em: (2023-07-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Por: Chio Sakai, et al.
Publicado em: (2024-07-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
Por: Nina B. Curkovic, MD, et al.
Publicado em: (2024-11-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
Por: Ravi Ranjan Pradhan, et al.
Publicado em: (2019-01-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
Por: Ryota Otoshi, et al.
Publicado em: (2020-03-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Por: Ian Pavord, et al.
Publicado em: (2023-04-01)